PARP inhibitors (PARPi) have shown promise in treating acute myeloid leukemia (AML) and other blood cancers, particularly in cases with specific genetic alterations such as RUNX1-RUNX1T1, PML-RARA, FLT3, and IDH1/2 mutations 32. The gene discussed is RUNX1; the disease is acute myeloid leukemia.